DTL
FULC icon

Dynamic Technology Lab’s Fulcrum Therapeutics FULC Stock Holding History

Dynamic Technology Lab’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,652
Closed -$94K – 1241
2022
Q3 		$94K Buy
+11,652
New +$83.4K 0.01% 1024

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Dynamic Technology Lab's FULC Position: Q4 2022 in Review

Dynamic Technology Lab sold out of Fulcrum Therapeutics (FULC) in Q4 2022, closing a stake of 11,652 shares — an estimated $94K sold.

Dynamic Technology Lab first reported a position in FULC in Q3 2022 and held it in 1 quarter. The position peaked at $94K in Q3 2022. 110 funds tracked by Wall St. Rank hold FULC as of Q4 2022.

  • Dynamic Technology Lab reported no remaining Fulcrum Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Dynamic Technology Lab sold 11,652 Fulcrum Therapeutics shares in Q4 2022, an estimated $94K.
  • Dynamic Technology Lab first reported a position in Fulcrum Therapeutics in Q3 2022 and held it in 1 quarter.
  • Dynamic Technology Lab's Fulcrum Therapeutics position peaked at $94K in Q3 2022.
  • 110 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2022.

Based on Dynamic Technology Lab's 13F filing for Q4 2022, filed 14 Feb 2023.